Jin Zhang1, Yan Liu. 1. Department of Breast Cancer, Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China. davidz9132002@yahoo.com
Abstract
PURPOSE: To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. PATIENTS AND METHODS: A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study. Among them, 600 patients were given CMF (CTX+MTX+5-Fu) regimen, 600 given CEF (CTX+E-ADM+5-Fu) regimen, and 425 given anthracyclines plus taxanes regimen, with mean follow-up time of 42 months. RESULTS: In CMF treatment group, the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%, P=0.0348); in node-positive subgroup, the 3-year DFS was 84.72% in HER2 over-expressed patients, and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen, anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative. CONCLUSION: HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemotherapy, but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.
PURPOSE: To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. PATIENTS AND METHODS: A total of 1625 primary breast cancerpatients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study. Among them, 600 patients were given CMF (CTX+MTX+5-Fu) regimen, 600 given CEF (CTX+E-ADM+5-Fu) regimen, and 425 given anthracyclines plus taxanes regimen, with mean follow-up time of 42 months. RESULTS: In CMF treatment group, the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%, P=0.0348); in node-positive subgroup, the 3-year DFS was 84.72% in HER2 over-expressed patients, and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen, anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative. CONCLUSION:HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancerpatients. HER2 over-expressed patients are resistant to CMF regimen chemotherapy, but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.
Authors: Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H Bramwell; Mark N Levine Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245
Authors: Daniel F Hayes; Ann D Thor; Lynn G Dressler; Donald Weaver; Susan Edgerton; David Cowan; Gloria Broadwater; Lori J Goldstein; Silvana Martino; James N Ingle; I Craig Henderson; Larry Norton; Eric P Winer; Clifford A Hudis; Matthew J Ellis; Donald A Berry Journal: N Engl J Med Date: 2007-10-11 Impact factor: 91.245
Authors: P P Di Fiore; J H Pierce; T P Fleming; R Hazan; A Ullrich; C R King; J Schlessinger; S A Aaronson Journal: Cell Date: 1987-12-24 Impact factor: 41.582
Authors: Christian Manginstar; Andi Asadul Islam; Daniel Sampepajung; William Hamdani; Agussalim Bukhari; Salman Ardy Syamsu; Nilam Smaradania; Muhammad Faruk Journal: Ann Med Surg (Lond) Date: 2021-02-10
Authors: Marlies Gijs; Gregory Penner; Garth B Blackler; Nathalie R E N Impens; Sarah Baatout; André Luxen; An M Aerts Journal: Pharmaceuticals (Basel) Date: 2016-05-19